O	0	1	A
O	2	12	randomized
O	13	18	trial
O	19	28	comparing
B-intervention	29	37	vascular
I-intervention	38	44	access
I-intervention	45	55	strategies
O	56	59	for
O	60	68	patients
O	69	78	receiving
O	79	91	chemotherapy
O	92	96	with
O	97	108	trastuzumab
O	109	112	for
O	113	118	early
O	118	119	-
O	119	124	stage
O	125	131	breast
O	132	138	cancer
O	138	139	.

O	140	151	Trastuzumab
O	151	152	-
O	152	157	based
O	158	170	chemotherapy
O	171	173	is
O	174	181	usually
O	182	194	administered
O	195	202	through
O	203	209	either
O	210	211	a
O	212	224	peripherally
O	225	233	inserted
O	234	241	central
O	242	250	catheter
O	251	252	(
O	252	256	PICC
O	256	257	)
O	258	260	or
O	261	262	a
B-control	263	270	totally
I-control	271	280	implanted
I-control	281	289	vascular
I-control	290	296	access
I-control	297	303	device
I-control	304	305	(
I-control	305	309	PORT
I-control	309	310	)
O	310	311	.

O	312	314	As
O	315	318	the
O	319	323	most
O	324	333	effective
O	334	338	type
O	339	341	of
O	342	348	access
O	349	351	is
O	352	359	unknown
O	359	360	,
O	361	362	a
O	363	374	feasibility
O	375	380	trial
O	380	381	,
O	382	387	prior
O	388	390	to
O	391	401	conducting
O	402	403	a
O	404	409	large
O	410	419	pragmatic
O	420	425	trial
O	425	426	,
O	427	430	was
O	431	441	undertaken
O	441	442	.

O	443	446	The
O	447	452	trial
O	453	464	methodology
O	465	473	utilized
O	474	477	the
O	478	488	integrated
O	489	496	consent
O	497	502	model
O	503	516	incorporating
O	517	521	oral
O	522	529	consent
O	529	530	.

B-eligibility	531	539	Patients
I-eligibility	540	549	receiving
I-eligibility	550	561	trastuzumab
I-eligibility	561	562	-
I-eligibility	562	567	based
I-eligibility	568	571	neo
I-eligibility	571	572	/
I-eligibility	572	580	adjuvant
I-eligibility	581	593	chemotherapy
I-eligibility	594	597	for
I-eligibility	598	603	early
I-eligibility	603	604	-
I-eligibility	604	609	stage
I-eligibility	610	616	breast
I-eligibility	617	623	cancer
O	624	628	were
O	629	639	randomized
O	640	642	to
O	643	644	a
O	645	649	PICC
O	650	652	or
O	653	657	PORT
O	658	667	insertion
O	667	668	.

B-outcome-Measure	669	680	Feasibility
O	681	684	was
O	685	694	reflected
O	695	702	through
O	703	704	a
O	705	716	combination
O	717	719	of
O	720	729	endpoints
O	729	730	;
O	731	738	however
O	738	739	,
O	740	743	the
O	744	745	a
O	746	752	priori
O	753	763	definition
O	764	766	of
O	767	778	feasibility
O	779	782	was
O	783	784	>
O	785	787	25
O	787	788	%
O	789	791	of
O	792	800	patients
O	801	811	approached
O	812	818	agreed
O	819	821	to
O	822	835	randomization
O	836	839	and
O	840	841	>
O	842	844	25
O	844	845	%
O	846	848	of
O	849	859	physicians
O	860	870	approached
O	871	879	patients
O	879	880	.

O	881	890	Secondary
O	891	899	outcomes
O	900	908	included
B-outcome-Measure	909	914	rates
I-outcome-Measure	915	917	of
I-outcome-Measure	918	922	line
I-outcome-Measure	922	923	-
I-outcome-Measure	923	933	associated
I-outcome-Measure	934	947	complications
I-outcome-Measure	948	952	such
I-outcome-Measure	953	955	as
I-outcome-Measure	956	966	thrombotic
I-outcome-Measure	967	973	events
I-outcome-Measure	974	983	requiring
I-outcome-Measure	984	999	anticoagulation
I-outcome-Measure	999	1000	,
I-outcome-Measure	1001	1005	line
I-outcome-Measure	1006	1016	infections
I-outcome-Measure	1017	1019	or
I-outcome-Measure	1020	1029	phlebitis
O	1029	1030	.

O	1031	1037	During
O	1038	1041	the
O	1042	1047	study
O	1048	1054	period
O	1054	1055	,
O	1056	1057	4
O	1057	1058	/
O	1058	1060	15
O	1061	1062	(
O	1062	1064	26
O	1064	1065	.
O	1065	1066	7
O	1066	1067	%
O	1067	1068	)
O	1069	1076	medical
O	1077	1088	oncologists
O	1089	1099	approached
O	1100	1108	patients
O	1109	1114	about
O	1115	1120	study
O	1121	1134	participation
O	1134	1135	.

O	1136	1138	Of
B-total-participants	1139	1141	59
O	1142	1150	patients
O	1151	1161	approached
O	1161	1162	,
B-total-participants	1163	1165	56
O	1166	1167	(
O	1167	1169	94
O	1169	1170	.
O	1170	1171	9
O	1171	1172	%
O	1172	1173	)
O	1174	1180	agreed
O	1181	1183	to
O	1184	1197	randomization
O	1197	1198	,
B-intervention-participants	1199	1201	29
O	1202	1203	(
O	1203	1205	51
O	1205	1206	.
O	1206	1207	8
O	1207	1208	%
O	1208	1209	)
O	1210	1214	were
O	1215	1225	randomized
O	1226	1228	to
O	1229	1233	PICC
O	1234	1237	and
B-control-participants	1238	1240	27
O	1241	1242	(
O	1242	1244	48
O	1244	1245	.
O	1245	1246	2
O	1246	1247	%
O	1247	1248	)
O	1249	1251	to
O	1252	1256	PORT
O	1257	1263	access
O	1263	1264	.

O	1265	1272	Overall
O	1272	1273	,
B-iv-bin-percent	1274	1276	17
I-iv-bin-percent	1276	1277	.
I-iv-bin-percent	1277	1278	2
I-iv-bin-percent	1278	1279	%
O	1280	1281	(
B-iv-bin-abs	1281	1282	5
O	1282	1283	/
B-intervention-participants	1283	1285	29
O	1285	1286	)
O	1287	1290	and
B-cv-bin-abs	1291	1293	14
I-cv-bin-abs	1293	1294	.
I-cv-bin-abs	1294	1295	8
I-cv-bin-abs	1295	1296	%
O	1297	1298	(
B-cv-bin-abs	1298	1299	4
O	1299	1300	/
B-control-participants	1300	1302	27
O	1302	1303	)
O	1304	1306	of
O	1307	1315	patients
O	1316	1319	had
O	1320	1322	at
O	1323	1328	least
O	1329	1332	one
B-outcome	1333	1337	line
I-outcome	1337	1338	-
I-outcome	1338	1348	associated
I-outcome	1349	1361	complication
O	1362	1364	in
O	1365	1368	the
O	1369	1373	PICC
O	1374	1377	and
O	1378	1382	PORT
O	1383	1387	arms
O	1388	1400	respectively
O	1400	1401	.

O	1402	1405	The
O	1406	1411	study
O	1412	1415	was
O	1416	1426	terminated
O	1427	1432	early
O	1433	1436	due
O	1437	1439	to
O	1440	1444	slow
O	1445	1452	accrual
O	1452	1453	.

O	1454	1457	The
O	1458	1463	study
O	1464	1467	met
O	1468	1471	its
O	1472	1483	feasibility
O	1484	1493	endpoints
O	1494	1498	with
O	1499	1506	respect
O	1507	1509	to
O	1510	1517	patient
O	1518	1521	and
O	1522	1531	physician
O	1532	1542	engagement
O	1542	1543	.

O	1544	1551	However
O	1551	1552	,
O	1553	1556	the
O	1557	1561	slow
O	1562	1566	rate
O	1567	1569	of
O	1570	1577	accrual
O	1578	1579	(
O	1579	1581	56
O	1582	1590	patients
O	1591	1593	in
O	1594	1595	2
O	1596	1601	years
O	1601	1602	)
O	1603	1608	means
O	1609	1613	that
O	1614	1624	conducting
O	1625	1626	a
O	1627	1632	large
O	1633	1642	pragmatic
O	1643	1648	trial
O	1649	1654	would
O	1655	1662	require
O	1663	1673	additional
O	1674	1684	strategies
O	1685	1687	to
O	1688	1692	make
O	1693	1697	such
O	1698	1699	a
O	1700	1705	study
O	1706	1714	possible
O	1714	1715	.

O	1716	1730	ClinicalTrials
O	1730	1731	.
O	1732	1735	gov
O	1736	1746	Identifier
O	1746	1747	:
O	1748	1759	NCT02632435
O	1759	1760	.
